Berman Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | $88K | Buy |
469
+55
| +13% | +$10.3K | 0.01% | 478 |
|
|
2021
Q2 | $70K | Buy |
414
+266
| +180% | +$45K | 0.01% | 467 |
|
|
2021
Q1 | $20K | Sell |
148
-56
| -27% | -$7.57K | ﹤0.01% | 786 |
|
|
2020
Q4 | $26K | Buy |
204
+15
| +8% | +$1.91K | 0.01% | 598 |
|
|
2020
Q3 | $27K | Buy |
189
+58
| +44% | +$8.29K | 0.01% | 501 |
|
|
2020
Q2 | $19K | Buy |
131
+42
| +47% | +$6.09K | 0.01% | 550 |
|
|
2020
Q1 | $9K | Buy |
89
+45
| +102% | +$4.55K | ﹤0.01% | 680 |
|
|
2019
Q4 | $5K | Hold |
44
| – | – | ﹤0.01% | 958 |
|
|
2019
Q3 | $3K | Buy |
44
+34
| +340% | +$2.32K | ﹤0.01% | 1053 |
|
|
2019
Q2 | $0 | Sell |
10
-47
| -82% | – | ﹤0.01% | 1457 |
|
|
2019
Q1 | $5K | Buy |
57
+52
| +1,040% | +$4.56K | ﹤0.01% | 844 |
|
|
2018
Q4 | $0 | Buy |
+5
| New | – | ﹤0.01% | 1120 |
|